FDA Receives Repros' Submission for Special Protocol Assessment Documentation for Pivotal Studies for Androxal
Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced it has received confirmation of delivery of the required documentation for Special Protocol Assessment of its Androxal® Phase 3 pivotal studies to the FDA. Per the Prescription Drug User Fee Act ("PDUFA"), the FDA has 45 calendar days to provide comments back to Repros.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.